Rigel Pharmaceuticals (RIGL)
NASDAQ:RIGL
Want to see RIGL full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.21Last Year’s EPS
3.28Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a generally positive commercial and strategic outlook: strong top-line product growth (26% YoY overall; 31% YoY for TAVALISSE and REZLIDHIA), clear 2026 guidance and a pathway to full-year profitability, alongside promising early clinical data for R289 and expanded international partner revenues. Offsetting risks include rising operating expenses, a modest decline in quarterly net income and cash, seasonal Q1 reimbursement headwinds, a slower-growing GAVRETO franchise, and the termination of the Lilly collaboration for the RIPK1 asset (creating program-level uncertainty). On balance, the highlights—robust product sales growth, maintained guidance, pipeline progress and improved financing flexibility—outweigh the lowlights.Company Guidance
Strong Quarterly Net Product Sales Growth
Net product sales of $54.9M in Q1 2026, up 26% year-over-year (+$11.3M vs Q1 2025), driven by across‑portfolio strength and improving demand in March.
TAVALISSE Outperformance
TAVALISSE net product sales of $37.3M in Q1 2026, up 31% year-over-year, driven by stronger demand and a favorable gross-to-net comparison versus prior year.
REZLIDHIA Rapid Growth and Commercial Momentum
REZLIDHIA net product sales of $8.0M in Q1 2026, up 31% year-over-year, with growing breadth and depth in academic accounts and focused efforts to expand adoption in community settings.
GAVRETO Stable Contributor
GAVRETO net product sales of $9.6M in Q1 2026, up 7% year-over-year, representing a stable, recurring revenue contribution (~$10M quarterly level).
Total Revenue and Contract Revenues
Total revenue of $58.8M in Q1 2026, including $3.9M of contract/collaboration revenues from partners (Grifols, Kissei, Medison) expanding international availability.
Profitability and Financial Guidance Maintained
Company reiterated 2026 guidance: total revenue $275M–$290M, net product sales $255M–$265M, contract revenues $20M–$25M, and expects positive net income for full-year 2026.
R289 Clinical Progress with Promising Early Efficacy
R289 (dual IRAK1/4 inhibitor) Phase Ib dose-escalation data: in 18 evaluable patients at ≥500 mg, 6 (33%) achieved ≥8-week red cell transfusion independence (median duration ~23 weeks; median time to onset ~2 months); generally well tolerated with low incidence of grade 3/4 cytopenias/infections; Fast Track and Orphan Drug designations in place.
Operational and Balance Sheet Strength
Achieved profitability in Q3 2024 and maintained financial discipline; ended Q1 2026 with $146.7M cash, cash equivalents and short-term investments; restructured debt to a $40M revolving credit facility (option to $60M) for flexible financing.
Business Development Focus
Clear strategy to in-license or acquire late-stage hematology/oncology assets with potential near-term launches (next 3 years) to leverage existing infrastructure and accelerate revenue.
RIGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RIGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $28.09 | $26.67 | -5.06% |
Mar 03, 2026 | $33.02 | $29.63 | -10.27% |
Nov 04, 2025 | $28.38 | $37.85 | +33.37% |
Aug 05, 2025 | $24.24 | $29.81 | +22.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rigel Pharmaceuticals (RIGL) report earnings?
Rigel Pharmaceuticals (RIGL) is schdueled to report earning on Aug 04, 2026, After Close (Confirmed).
What is Rigel Pharmaceuticals (RIGL) earnings time?
Rigel Pharmaceuticals (RIGL) earnings time is at Aug 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RIGL EPS forecast?
RIGL EPS forecast for the fiscal quarter 2026 (Q2) is 0.21.